Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
PVLA
PVLA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest PVLA ETF News Today | Earnings, Events & Price Alerts
PVLA News
Palvella Closes $230 Million Upsized Public Offering
2d ago
Newsfilter
Significant Milestones in Biotech Sector This Week
5d ago
NASDAQ.COM
Palvella Therapeutics Prices $200 Million Upsized Public Offering
6d ago
NASDAQ.COM
Palvella Therapeutics Successfully Prices Upsized Public Offering
6d ago
Yahoo Finance
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
US Stocks Rebound Led by Software and Chipmakers
Feb 25 2026
NASDAQ.COM
US Stocks Rebound Led by Software and Chipmakers
Feb 24 2026
NASDAQ.COM
U.S. Stocks Rise with Dow Jones Up Over 400 Points
Feb 24 2026
Benzinga
Palvella Therapeutics Shares Surge 30% After Successful Trial Results
Feb 24 2026
seekingalpha
US Stocks Rebound Slightly as Software Shares Recover
Feb 24 2026
NASDAQ.COM
Palvella Therapeutics SELVA Trial Success Boosts Stock
Feb 24 2026
Benzinga
U.S. Stocks Mixed in Morning Trade; Dow Jones Up Over 100 Points
Feb 24 2026
Benzinga
Palvella's QTORIN Gel Shows Positive Phase 3 Results for Rare Lymphatic Condition
Feb 24 2026
NASDAQ.COM
Palvella Therapeutics Shares Surge 45% on Positive Phase 3 Study Results
Feb 24 2026
stocktwits
Palvella's QTORIN™ Rapamycin Shows Significant Phase 3 Trial Results for Microcystic Lymphatic Malformations
Feb 24 2026
Newsfilter
Palvella Therapeutics to Present Phase 3 Trial Results for QTORIN Gel
Feb 24 2026
NASDAQ.COM
Show More News
